Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why BioCryst Pharmaceuticals Popped Today

By Cory Renauer - Sep 23, 2019 at 5:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are thrilled with a new addition to BioCryst's board of directors.

What happened

Shares of BioCryst Pharmaceuticals ( BCRX -2.27% ), a clinical-stage biotech focused on treating rare diseases, popped after the company announced the appointment of a new board member. The stock jumped 15.7% higher in midday trading and ended Monday's session with a 12.9% gain.

So what

Investor-relations departments have to issue a release whenever members of a board of directors come and go, but they rarely move biotech stocks this far. BioCryst's stock soared today because its new board member is Dr. Helen Thackray, the chief medical officer (CMO) of GlycoMimetics ( GLYC 1.31% ).

Person on a podium holding an upward-pointing arrow

Image source: Getty Images.

Dr. Thackray adds clinical rare-disease experience through her work as a pediatrician, which could be helpful if BioCryst's lead candidate, BCX7353, launches in 2020.

Now what

BioCryst's lead candidate is a small-molecule drug that inhibits the same enzyme implicated in hereditary angioedema (HAE) as an antibody marketed by Takeda Pharmaceutical ( TKPHF 4.78% ). Phase 3 trial data for Takeda's drug, Takhzyro, showed it lowered HAE attack rates by 70% or better for 89% of patients. While it's dangerous to compare results from different populations, BCX7353 only helped 50% of HAE patients meet the same goal.

Dr. Thackray's role on BioCryst's board of directors will be very different from the one she plays as CMO at GlycoMimetics. It's hard to see how she'll be able to improve underwhelming results from BCX7353's phase 3 trial. Those results might be good enough to earn an approval from the Food and Drug Administration, but a successful launch doesn't seem likely.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
BCRX
$11.18 (-2.27%) $0.26
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
TKPHF
$27.88 (4.78%) $1.27
GlycoMimetics Stock Quote
GlycoMimetics
GLYC
$1.55 (1.31%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.